Alto Neuroscience ANRO Business Segments — G&A

Similar metrics at other companies

ABUSReportable Segment — G&A

$5.89M+1.0%

PEGAReportable Segment — G&A

$48.57M+43.6%

PGNYReportable segment — G&A

$30.81M-9.0%

PCVXReportable Segment — G&A

$33.07M+1.3%

DLBReportable Segment — G&A

$64.14M+10.6%

UPWKReportable Segment — G&A

$25.56M+11.4%

Questions, answered.

What is Alto Neuroscience's business segments — G&A?

Alto Neuroscience (ANRO) reported business segments — G&A of $4.09M in Q1 2026.

How has Alto Neuroscience's business segments — G&A changed year-over-year?

Alto Neuroscience's business segments — G&A increased by 34.4% year-over-year, from $3.04M to $4.09M.

What is the long-term trend for Alto Neuroscience's business segments — G&A?

Over 2 years (2023 to 2025), Alto Neuroscience's business segments — G&A has grown at a 57.5% compound annual growth rate (CAGR), from $4.38M to $10.87M.

What does business segments — G&A mean?

This metric includes the overhead and support costs necessary to operate the business, such as legal, accounting, facility, and corporate administrative expenses. It reflects the fixed cost structure required to maintain corporate governance and operational infrastructure outside of direct research activities. Investors use this to evaluate the company's operational leverage and the efficiency of its corporate support functions.